Kanada - angleščina - Health Canada

teva canada limited - fentanyl - patch - 100mcg - fentanyl 100mcg - opiate agonists

Kanada - angleščina - Health Canada

teva canada limited - fentanyl - patch - 12mcg - fentanyl 12mcg - opiate agonists

Združene države Amerike - angleščina - NLM (National Library of Medicine)

depomed, inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - lazanda is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least: 60 mg of oral morphine per day, 25 mcg of transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid for a week or longer. patients must remain on around-the-clock opioids when taking lazanda. limitations of use: - not for use in opioid non-tolerant patients. - not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency department [see contraindications (4)]. - as a part of the tirf rems access program, lazanda may be disp

Združene države Amerike - angleščina - NLM (National Library of Medicine)

archimedes pharma us inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - lazanda (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking at least: 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer. patients must remain on around-the-clock opioids when taking lazanda. lazanda is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could occur in patients not taking chronic opioids. for this reason, lazanda is contraindicated in the management of acute or postoperative pain, including headache/migraine, or dental pain. [4] lazanda is intended to be prescribed only by healthcare professionals who are knowledgeable of and

Kanada - angleščina - Health Canada

hikma canada limited - fentanyl (fentanyl citrate) - solution - 50mcg - fentanyl (fentanyl citrate) 50mcg - opiate agonists

Kanada - angleščina - Health Canada

fresenius kabi canada ltd - fentanyl (fentanyl citrate) - solution - 50mcg - fentanyl (fentanyl citrate) 50mcg - opiate agonists

Armenija - angleščina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

kalceks jsc - fentanyl (fentanyl citrate) - solution for injection - 0,05mg/ml

Armenija - angleščina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

kalceks jsc - fentanyl (fentanyl citrate) - solution for injection - 0,05mg/ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bryant ranch prepack - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60　mg morphine per day, 25 mcg transdermal fentanyl per hour, 30　mg oral oxycodone per day, 8　mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see warnings and precautions (5.1)] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bryant ranch prepack - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. fentanyl transdermal system is contraindicated in the followin